Medical laboratory scientist

LifeLabs Celebrates National Medical Laboratory Week Recognizing Compassionate, Passionate, and Innovative Professionals

Retrieved on: 
星期一, 四月 15, 2024
Health, Society, Medical laboratory scientist

Toronto, April 15, 2024 (GLOBE NEWSWIRE) -- This week, LifeLabs joins in celebrating the annual National Medical Laboratory Week, a significant event organized by the Canadian Society for Medical Laboratory Science.

Key Points: 
  • Toronto, April 15, 2024 (GLOBE NEWSWIRE) -- This week, LifeLabs joins in celebrating the annual National Medical Laboratory Week, a significant event organized by the Canadian Society for Medical Laboratory Science.
  • This week-long celebration acknowledges and honours the invaluable contributions of medical laboratory professionals across Canada.
  • Throughout Medical Laboratory Week and beyond, LifeLabs reaffirms its unwavering commitment to providing high-quality services prioritizing Canadians' health and well-being.
  • By combining compassion, innovation, and expertise, LifeLabs continues to set the standard for excellence in medical laboratory services.

BYG4lab®, Innovator of Next Generation Software Suites for Laboratories and Diagnostics, Appoints Tim Bickley as VP Sales US to Spearhead Entry into US market

Retrieved on: 
星期三, 四月 10, 2024
Averett University, Society, ASM, Infection, Laboratory, Epidemiology, ASCP, MLS, Medical laboratory scientist, LIS, Health technology, Diagnosis, HIMSS, Patient, Microbiology, Data management, EWC, Health, MBA, Health information management, Medical college, IVD, Medical device

This key executive appointment and expansion marks a significant milestone to introduce the company’s innovative laboratory solutions to the US.

Key Points: 
  • This key executive appointment and expansion marks a significant milestone to introduce the company’s innovative laboratory solutions to the US.
  • BYG4lab is a global software company specializing in clinical laboratory and diagnostic data management solutions.
  • Prior to joining BYG4lab, Tim held VP Sales and Marketing roles at leading laboratory information solution vendors.
  • ASM - American Society for Microbiology, June 13th - 17th, Atlanta, GA.
    ADLM - Association for Diagnostics & Laboratory Management, July 28 - August 1st, Chicago, IL.

Sequel’s twiist™ Automated Insulin Delivery System Receives FDA 510(k) Clearance

Retrieved on: 
星期一, 三月 18, 2024
CGM, Organization, Cell, DEKA, Entrepreneurship, AID, Insulin, Diabetes, Patient, Life, Pancreas, FDA, Medical laboratory scientist, Food, Pharmaceutical industry

MANCHESTER, N.H., March 18, 2024 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, today announced its partner, DEKA Research & Development Corp., has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the innovative twiist™ Automated Insulin Delivery (AID) system powered by Tidepool.

Key Points: 
  • MANCHESTER, N.H., March 18, 2024 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, today announced its partner, DEKA Research & Development Corp., has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the innovative twiist™ Automated Insulin Delivery (AID) system powered by Tidepool.
  • The twiist AID system, which will be commercialized by Sequel Med Tech, LLC, is the first drug delivery system that directly measures the volume and flow of insulin delivered with every micro-dose.
  • “The clearance of the twiist AID system is a pivotal first step in Sequel’s quest to make day-to-day life easier for people with type 1 diabetes.
  • The twiist system was designed from the start to integrate with the latest available innovation, and it represents the next generation of insulin delivery,” said Kamen.

AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture

Retrieved on: 
星期四, 四月 4, 2024
Health, Oncology, Cardiology, Medical Devices, Radio, MED, Dialysis, Pulmonary embolism, Growth, Patient, News, Nanoknife, Cancer, Public expenditure, Table, APEX, Quality of life, PICC, Radiofrequency ablation, IP, GAAP, Patent, Starburst, FDA, Medical laboratory scientist, Pharmaceutical industry

Net sales for the third quarter of fiscal year 2024 were $66.0 million, an increase of 8.0% compared to the prior-year quarter.

Key Points: 
  • Net sales for the third quarter of fiscal year 2024 were $66.0 million, an increase of 8.0% compared to the prior-year quarter.
  • U.S. net sales in the third quarter of fiscal 2024 were $55.8 million, an increase of 5.9% from sales of $52.7 million a year ago.
  • GAAP reported gross margin was 47.7%, a decrease of 250 basis points compared to the third quarter of fiscal 2023.
  • On a pro forma basis, gross margin for the third quarter of fiscal 2024 was 51.1%, a decline of 290 basis points from the third quarter of fiscal 2023.

AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million

Retrieved on: 
星期四, 二月 15, 2024
Oncology, Medical Supplies, Health, Surgery, Cardiology, Biotechnology, Acquisition, Marketing, Sale, Cadwalader, Medical laboratory scientist, Radiofrequency ablation, Dialysis, PICC, Nanoknife, Cadwalader, Wickersham & Taft, UBS, Cancer, Security (finance)

The transaction consists of AngioDynamics’ PICC, Midline and tip location products.

Key Points: 
  • The transaction consists of AngioDynamics’ PICC, Midline and tip location products.
  • This combined portfolio of products contributed approximately $43.5 million in annual sales during AngioDynamics’ fiscal year 2023.
  • These products contributed approximately $5.5 million in annual sales during AngioDynamics’ fiscal year 2023.
  • The divestiture of the PICC and Midline businesses, together with the discontinuance of the radiofrequency ablation and Syntrax businesses, will reduce full-year fiscal 2024 revenue by approximately $50 million.

AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance

Retrieved on: 
星期五, 一月 5, 2024
Health, General Health, Nanoknife, Quality of life, SKU, Table, Public expenditure, Dialysis, Education, News, Cancer, Rationalization, MED, Unless, Thrombectomy, Growth, Patient, Medical laboratory scientist, GAAP, EPS, Pharmaceutical industry

Net sales for the second quarter of fiscal year 2024 were $79.1 million, an increase of 2.7% compared to the prior-year quarter.

Key Points: 
  • Net sales for the second quarter of fiscal year 2024 were $79.1 million, an increase of 2.7% compared to the prior-year quarter.
  • AngioVac sales were $5.4 million in the quarter, a decline of 10.8% from the second quarter of fiscal 2023.
  • U.S. net sales in the second quarter of fiscal 2024 were $64.0 million, an increase of 0.6% from sales of $63.6 million a year ago.
  • Gross margin for the second quarter of fiscal 2024 was 50.9%, a decrease of 80 basis points from gross margin of 51.7% in the second quarter of fiscal 2023.

Global Bio-India 2023 attracts global interest for India's $300 billion biotech potential from companies, academia, and start-ups

Retrieved on: 
星期一, 十二月 4, 2023
Ministry, Department of Biotechnology, University of Illinois Urbana-Champaign, FDI, D, Ministry of Science, Public, PMO, Ethics, Government, Primary energy, SME, Ecosystem, USD, Independent, Valorisation, University, Medical laboratory scientist, Growth, Employment, DBT, Lignin, Pandemic, Renewable energy, Pharmaceutical industry, Science, Biotechnology, Pension, Health care, Pharma

Global Bio-India 2023 would be the largest congregation of biotech startups.

Key Points: 
  • Global Bio-India 2023 would be the largest congregation of biotech startups.
  • The central theme of Global Bio-India 2023 is Biotech Innovation and Bio-manufacturing.
  • Global Bio-India 2023 is not just an event; it's an opportunity to shape the future of biotechnology on a global scale  ( Source ).
  • The participation of US biotech leaders in India underscores the strategic importance of the collaboration between two global biotechnology giants.

LifeLabs and BCIT Collaborate to Launch Innovative Global Chapter on Blood Tests in Open Education Pathology Textbook

Retrieved on: 
星期四, 十月 26, 2023
MLT, United Kingdom, Education, Pathology, UBC, BCIT, British Columbia Institute of Technology, ASCP, Medical laboratory scientist, Multimedia, Learning, Curriculum, Student, Provost, Blood, Textbook, Nursing

This new chapter, centred around blood and blood tests, offers an engaging and informative resource that transcends borders, benefiting healthcare professionals, students, and curious minds across the globe.

Key Points: 
  • This new chapter, centred around blood and blood tests, offers an engaging and informative resource that transcends borders, benefiting healthcare professionals, students, and curious minds across the globe.
  • "In our collaboration with BCIT, we've contributed to a resource that educates and inspires a diverse worldwide audience," said Charles Brown, President and CEO of LifeLabs.
  • “This new Open Education Pathology Textbook chapter exemplifies the strength of BCIT in working with industry to reduce barriers to education,” said Jennifer Figner, Provost and Vice President, Academic, BCIT.
  • This collaborative initiative between LifeLabs and BCIT provides a valuable resource for healthcare professionals and students while reinforcing the global impact of open education initiatives in the medical field.

AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance

Retrieved on: 
星期三, 十月 4, 2023
Oncology, Medical Supplies, Health, Medical Devices, Surgery, Health Technology, Cardiology, International, Table, Cancer, Quality of life, GAAP, Sale, Public expenditure, MED, Nanoknife, EBITDA, Patient, Growth, News, Medical laboratory scientist, Pharmaceutical industry, Video game, Security (finance), Dialysis

AngioVac sales were $6.3 million in the quarter, a decline of 7.7% year over year and up 3.6% sequentially from the fourth fiscal quarter of FY23.

Key Points: 
  • AngioVac sales were $6.3 million in the quarter, a decline of 7.7% year over year and up 3.6% sequentially from the fourth fiscal quarter of FY23.
  • U.S. net sales in the first quarter of fiscal 2024 were $64.4 million.
  • The Company recorded net income of $45.9 million, or earnings per share of $1.15, in the first quarter of fiscal 2024.
  • Adjusted EBITDA in the first quarter of fiscal 2024, excluding the items shown in the reconciliation table below, was $0.8 million.

BioProtect Secures $28M to Commercialize its Biodegradable Balloon for Rectal Protection During Prostate Cancer Radiation Therapy

Retrieved on: 
星期三, 九月 27, 2023
Consensus, Radiation, Investment, ASTRO, Toxicity, Patient, FDA, Vincent Tchenguiz, MVM, Society, Medical laboratory scientist, Prostate cancer, Medical device

The round was led by MVM Partners, with participation from current investors: Triventures, KB Investments, Peregrine Ventures, Almeda Ventures, and Consensus Business Group of Vincent Tchenguiz.

Key Points: 
  • The round was led by MVM Partners, with participation from current investors: Triventures, KB Investments, Peregrine Ventures, Almeda Ventures, and Consensus Business Group of Vincent Tchenguiz.
  • Proceeds from this financing will support US commercialization of the BioProtect Balloon Implant System, which recently received FDA clearance for rectal protection during radiation therapy for prostate cancer.
  • "We believe that our balloon has the potential to revolutionize rectal protection from radiation toxicity during prostate cancer radiation therapy," said BioProtect's CEO, Itay Barnea.
  • "To-date, our spacer has been successfully implanted in over 2,000 patients worldwide and has proven to be safe and effective.